Investing For The Future

“Our multi-purpose highly potent API (HPAPI) plant and large-scale manufacturing facility in Edinburgh offer full cGMP production capabilities for APIs and controlled substances. In February 2023 we expanded our capabilities at the Edinburgh site in handling highly potent APIs and intermediates, enabling growth in the generic opioid analgesic and anti-addiction markets, as well as supporting the growing demands of Veranova’s existing customer base and unlocking future growth.

“At Veranova, health, safety and quality are paramount in everything we do. It’s ingrained in our culture. The expansion has really allowed us to build on this aspect of the business. We have significantly improved our containment capabilities by the addition of engineering controls and enhanced layers of protection. Not only does this better protect our employees and products, it also allows us to handle a far wider range of materials, processes and products. It has given us additional capacity to grow into a more diverse range of potential pharmaceutical products.”

David Payne, Veranova’s VP, General Manager, Scotland, recently spoke to Manufacturing Today to discuss how Veranova is expanding its portfolio to meet increased industry demands.

Read the full article on page 172 of Manufacturing Today, September 2023 issue